Rangering i aksjer
#33870
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Aksjekurs
$0.5475
Sist synkronisert: 2026-08-14
Handel 20/20 Biolabs Inc. (AIDX)
Pris AIDX pris med markedsverdi på B
Markedsverdi av 20/20 Biolabs Inc.(AIDX)
Markedsverdi: $6.71M
Per August 2026 har 20/20 Biolabs Inc. en markedsverdi på $6.71M. Dette gjør 20/20 Biolabs Inc. til det 33870th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for 20/20 Biolabs Inc. fra 2026 til 2026
AIDX sammenlignet med topp 5 mest populære stocks
| Pris på AIDX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+81,276,656.64%
|
|
|
|
|
$4.490T
|
+66,937,378.02%
|
|
|
|
|
$4.162T
|
+62,053,302.40%
|
|
|
|
|
$3.676T
|
+54,807,023.79%
|
|
|
|
|
$2.833T
|
+42,235,061.84%
|
